Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer

Research output: Contribution to journalArticle


Background: Prostate adenocarcinoma is generally characterized by slow progression although some phenotypes have a more aggressive behavior with tendency to local invasion and distant metastases, mainly to bones. Better specific care could be provided to the aggressive phenotype-group of patients if pre-surgical identification were available. Material and Methods: Correlations between pre-surgical levels of 6 blood molecules and pathological tumour staging, post-surgical Gleason score and disease-free survival have been observed. Plasma and sera from 162 men affected by prostate adenocarcinoma were analysed with ELISA to assess levels of neovascularization-related molecule (VEGF), endothelial cell adhesion molecule (VCAM), extracellular matrix destruction-related molecules (MMP-2, MMP-9), and tissue inhibitors of metalloproteinase (TIMP-1 and TIMP-2). Results: The median values of serum determinations were for VEGF 279 pg/ml, VCAM 633 ng/ml, MMP-2 206 ng/ml and MMP-9 614 ng/ml. Plasma medians (ng/ml) were 94 for TIMP-1 and 90 for TIMP-2. Patients with VCAM values > 633 ng/ml had a worse disease-free survival than patients with values

Original languageEnglish
Pages (from-to)199-206
Number of pages8
JournalCurrent Cancer Drug Targets
Issue number3
Publication statusPublished - May 2008


  • Blood marker
  • Bone metastasis
  • MMP
  • MMP-2
  • Prognosis
  • Prostate cancer
  • TIMP
  • VCAM
  • VEGF

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Cancer Research

Fingerprint Dive into the research topics of 'Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer'. Together they form a unique fingerprint.

  • Cite this